Phase I study of irinotecan combined with mitomycin-C and 5-fluorouracil for gynecological malignancies: The JGOG study

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2933-2939

  Kokawa, Katsuji ^a   Umesaki, Naohiko ^a   Yamamoto, Kaichiro ^b   Takizawa, Ken ^c   Konishi, Ikuo ^d   Hasegawa, Kazuo ^e  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Inamino Hospital   (Japan)

Author keywords

5 FU; CPT 11; Gynecological malignancy; MMC; New combined chemotherapy; Phase I study

Indexed keywords

FLUOROURACIL; IRINOTECAN; MITOMYCIN C;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG TOLERANCE; HUMAN; HYSTERECTOMY; LEUKOPENIA; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; MITOMYCIN; OVARIAN NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 55749104415     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000.
2. Enomoto T, Kuragaki C, Yamasaki M, Sugita N, Otsuki Y, Ikegami H, Matsuzaki N, Yamada T, Wakimoto A and Murata Y; for the Gynecologic Oncology Group of Osaka: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22: 444 (#1797), 2003.
3. Ozols RF, Bundy BN, Greer BE, Fowley JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R: Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21: 3194-3200, 2003.
4. du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W and Pfisterer J: Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329, 2003.
5. Shimizu Y, Umezawa S and Hasumi K: A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian cancer. Ann Acad Med Singapore 27: 650-656, 1998.
6. Smith HO, Tiffany MF, Quails CR and Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study. Gynecol Oncol 78: 97-105, 2000.
7. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL III, Walker JL and Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340: 1154-1161, 1999.
8. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence after concominant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358: 781-786,2001.
9. Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M, Fung MF and Browman G: Cancer Care Ontario Practice Guidelines Initiative Gynecology Disease Site Group: Concurrent cisplatinbased chemotherapy plus radiotherapy for cervical cancer - a meta-analysis. Clin Oncol 14: 203-212, 2002.
10. Berek JS, Castaldo TW, Hacker NF, Petrilli ES, Lagasse LD and Moore JG: Adenocarcinoma of the uterine cervix. Cancer 48: 2734-2741,1981.
11. Eifel PJ, Burke TW, Morris M and Smith TL: Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 59: 38-44, 1995.
12. Burke TW, Hoskins WJ, Heller PB, Shen MC, Weiser EB and Park RC: Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma. Obstet Gynecol 69: 382-385, 1987.
13. Shingleton HM, Bell MC, Fremgen A, Chmiel JS, Russell AH, Jones WB, Winchester DP and Clive RE: Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? Cancer 76: 1948-1955, 1995.
14. Peters WA III, Liu PY, Barrett RJ II, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr and Alberts DS: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18: 1606-1613, 2000.
15. Huang HJ, Chang TC, Hong JH, Tseng CJ, Chou HH, Huang KG and Lai CH: Prognostic value of age and histologic type in neoadjuvant chemotherapy plus radical surgery for bulky (> 4 cm) stage IB and UA cervical carcinoma. Int J Gynecol Cancer 13: 204-211,2003.
16. Umesaki N, Izumi R, Fushiki H, Hasegawa K, Kono I, Nishida M, Noguchi H, Okuda H, Sugimori H, Takizawa K, Udagawa Y, Yamamoto K, Tanaka T and Noda K: Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease. Gynecol Oncol 75: 142-144, 1999.
17. Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C and Sessa C: Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 8: 969-972, 1997.
18. Thigpen JT, Blessing JA, Fowler WC Jr and Hatch K: Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Treat Rep 70: 1097-1100, 1986.
19. Papadimitriou CA, Sards K, Moulopoulos LA, Fountzilas G, Anagnostopoulos A, Voulgaris Z, Gika D, Giannakoulis N, Diakomanolis E and Dimopoulos MA: Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 17: 761-766, 1999.
20. Wall ME, Wani MC, Cook CE and Palmar KH: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1996.
21. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T and Mutai M: Antitumor activity of 7-ethyl-10-[4-(1- piperidino)- 10-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5947, 1987.
22. Matsuzaki T, Yokokura T, Mutai M and Tsuruo T: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308-312, 1988.
23. Irvin WP, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ and Potkul RK: A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer 82: 328-333, 1998.
24. Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M and Ohashi Y: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58: 31-37, 2000.
25. Umesaki U, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K and Izumi R: Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol 95: 127-132, 2004.
26. Kokawa K, Nishimura R, Fujii T and Umesaki N: Neoadjuvant chemotherapy with irinotecan and mitomycin-C for locally advanced squamous cell carcinoma of the uterine cervix. Anticancer Res 27: 2721-2728, 2007.
27. Sugiyama T, Yakushiji M, Kamura T, Ikeda M, Umesaki N, Hasegawa K, Ishikawa M, Saji F, Hiura M, Takahashi T, Sato S, Ochiai K, Kikkawa F, Takeuchi S, Ohashi Y and Noda K for the Japan CPT-11 Study Group: Irinotecan (CPT-Il) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63: 16-22, 2002.
28. Nishino K, Aoki Y, Amikura T, Obata H, Sekine M, Yahata T, Fujita K and Tanaka K: Irinotecan hydrochloride (CPT-Il) and mitomycin C as the first-line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 97: 893-897,2005.
29. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000
30. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK and Miller LL: Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6: 81-91, 2001.
31. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B and Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786, 2007.
32. Look KY, Blessing JA, Valea FA, McGehee R, Manetta A, Webster KD and Andersen WA: Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 67: 255-258, 1997.
33. Hara K, Iwasaka T, Matsuo N, Nakao Y, Yokoyama M, Yamasaki F, Miura M and Sugimori H: Effects of single and combined application of anti-cancer drugs on cervical adenocarcinoma. I. Antitumor activity in vitro. Acta Obstet Gynecol Scand 74: 330-335, 1995.
34. Villalona-Calero MA and Kolesar JM: Mitomycin as a modulator of irinotecan anticancer activity. Oncology 16: 21-25, 2002.
35. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
36. Tobina K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, Narabayashi M, Fukutomi T, Kondo H, Shimoyama M and Suematu K; members of the Clinical Trial Review Committee of the Japan Clinical Oncology Group: Toxicity grading criteria of the Japan Clinical Oncology Group. JPN J Clin Oncol 23: 250-257, 1993.
37. Pamela G, Hai-Yen Sung, Sawaya GF. Changes in cervical incidence after three decades of screening US women less than 30 years old. Obstet Gynecol 702: 765-773, 2003.
38. Bulk S, Visser O, Rozendaal L, Verheijen RHM, Meijer CJLM. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 113: 1005-1009, 2005.